{"id":"NCT01467882","sponsor":"Debiopharm International SA","briefTitle":"Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty","officialTitle":"An Open-label, Non-comparative, Multicenter Study on the Efficacy, Safety, and Pharmacokinetics of Triptorelin Pamoate (Embonate) 22.5 mg 6-month Formulation in Patients Suffering From Central (Gonadotropin-dependent) Precocious Puberty","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-04","primaryCompletion":"2013-08","completion":"2014-07","firstPosted":"2011-11-09","resultsPosted":"2015-09-04","lastUpdate":"2017-07-28"},"enrollment":44,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Central Precocious Puberty"],"interventions":[{"type":"DRUG","name":"Triptorelin","otherNames":["Trelstar"]}],"arms":[{"label":"Triptorelin","type":"EXPERIMENTAL"}],"summary":"The study will investigate the efficacy, safety and pharmacokinetics of triptorelin 22.5 mg 6-month formulation in 44 patients suffering from central precocious puberty. The total study duration per patient will be 12 months (48 weeks).","primaryOutcome":{"measure":"Percentage of Children With Luteinizing Hormone (LH) Suppression to Prepubertal Levels 30 Minutes After Leuprolide Stimulation at Month 6","timeFrame":"Month 6","effectByArm":[{"arm":"Children","deltaMin":93.18,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":13,"countries":["United States","Chile","Mexico"]},"refs":{"pmids":["19332438","16995580","19189683","10969915"],"seeAlso":["http://www.debiopharm.com"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":44},"commonTop":["Headache","Nasopharyngitis","Upper respiratory tract infection","Cough","Gastroenteritis"]}}